摘要
目的探索骨髓增生异常综合征(MDS)发病机制研究领域的现状及发展趋势。方法以Web of Science核心合集为数据来源,结合CiteSpace软件的可视化功能,对2011年1月至2020年12月的MDS发病机制研究文献信息(期刊、作者、机构、国家、关键词、高被引文献)进行分析。结果共纳入941篇文献。发文量最多的期刊为Blood,发文量最多的作者是来自美国克利夫兰诊所的Jaroslaw P.Maciejewski。美国德克萨斯大学MD安德森癌症中心是发表文献最多的机构。发现13个关键词聚类和14个突现关键词,频数较高的关键词包括急性髓系白血病、造血干细胞、体细胞突变、基因表达等。结论MDS发病机制研究领域获得了长足的发展,其中主要研究方向包括克隆造血、体细胞基因突变、骨髓微环境与免疫异常,针对发病机制的各类新药研发将成为未来研究趋势。
Objective To explore the current status and development trend of the pathogenesis of myelodysplastic syndromes(MDS).Methods Using Web of Science core collection as data source,combined with the visualization function of CiteSpace software,the literature information(journals,authors,institutions,countries,keywords,and highly cited literatures)on the pathogenesis of MDS from January 2011 to December 2020 were analyzed.Results A total of 941 articles were included.The journal with the most publications was Blood,and the author with the most publications was Jaroslaw P.Maciejewski from the cleveland clinic in the United States.The university of Texas MD Anderson Cancer Center was the institution with the most published literature.A total of 13 keyword clusters and 14 emergent keywords were found.Keywords with higher frequency include acute myeloid leukemia,hematopoietic stem cells,somatic mutations,and gene expression,etc.Conclusion The research field of MDS pathogenesis has made great progress.The main research directions include clonal hematopoiesis,somatic gene mutation,bone marrow microenvironment,and immune abnormalities.The development of various new drugs for pathogenesis will become the future research trend.
作者
徐皓
陶雨晨
胡可心
薛婷婷
王艳璐
梁陈慧
董孝杰
陆嘉惠
XU Hao;TAO Yuchen;HU Kexin;XUE Tingting;WANG Yanlu;LIANG Chenhui;DONG Xiaojie;LU Jiahui(Department of Hematology,Shanghai Municipal Hospital of Traditional Chinese Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 200071,China)
出处
《中国医药导报》
CAS
2022年第16期88-92,共5页
China Medical Herald
基金
国家自然科学基金面上项目(81873286)
上海市科学技术委员会科技计划项目(20XD1403500、21Y31920400)
上海申康医院发展中心临床科技创新项目(SHDC12020128)。